27 related articles for article (PubMed ID: 38466537)
1. Convergent validity of EQ-5D with core outcomes in dementia: a systematic review.
Hussain H; Keetharuth A; Rowen D; Wailoo A
Health Qual Life Outcomes; 2022 Nov; 20(1):152. PubMed ID: 36403046
[TBL] [Abstract][Full Text] [Related]
2. Comparing the measurement equivalence of EQ-5D-5L across different modes of administration.
Mulhern B; O'Gorman H; Rotherham N; Brazier J
Health Qual Life Outcomes; 2015 Nov; 13():191. PubMed ID: 26612336
[TBL] [Abstract][Full Text] [Related]
3. An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand.
Dritsaki M; Petrou S; Williams M; Lamb SE
Health Qual Life Outcomes; 2017 Jan; 15(1):20. PubMed ID: 28118833
[TBL] [Abstract][Full Text] [Related]
4. The validity and responsiveness of the EQ-5D measure of health-related quality of life in an adolescent population with persistent major depression.
Byford S
J Ment Health; 2013 Apr; 22(2):101-10. PubMed ID: 23574502
[TBL] [Abstract][Full Text] [Related]
5. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
Tramontano AC; Schrag DL; Malin JK; Miller MC; Weeks JC; Swan JS; McMahon PM
Med Decis Making; 2015 Apr; 35(3):371-87. PubMed ID: 25670839
[TBL] [Abstract][Full Text] [Related]
6. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
[TBL] [Abstract][Full Text] [Related]
7. A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021).
Gnanasakthy A; Levy C; Norcross L; Doward L; Winnette R
Value Health; 2023 Jun; 26(6):893-901. PubMed ID: 36746305
[TBL] [Abstract][Full Text] [Related]
8. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
Mueller V; Wardley A; Paplomata E; Hamilton E; Zelnak A; Fehrenbacher L; Jakobsen E; Curtit E; Boyle F; Harder Brix E; Brenner A; Crouzet L; Ferrario C; Muñoz-Mateu M; Arkenau HT; Iqbal N; Aithal S; Block M; Cold S; Cancel M; Hahn O; Poosarla T; Stringer-Reasor E; Colleoni M; Cameron D; Curigliano G; Siadak M; DeBusk K; Ramos J; Feng W; Gelmon K
Eur J Cancer; 2021 Aug; 153():223-233. PubMed ID: 34214937
[TBL] [Abstract][Full Text] [Related]
9. How Do Respondents Interpret and View the EQ-VAS? A Qualitative Study of Three Asian Populations.
Tan RL; Yang Z; Igarashi A; Herdman M; Luo N
Patient; 2021 Mar; 14(2):283-293. PubMed ID: 32944897
[TBL] [Abstract][Full Text] [Related]
10. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.
Kennedy-Martin M; Slaap B; Herdman M; van Reenen M; Kennedy-Martin T; Greiner W; Busschbach J; Boye KS
Eur J Health Econ; 2020 Nov; 21(8):1245-1257. PubMed ID: 32514643
[TBL] [Abstract][Full Text] [Related]
11. EQ-5D and the EuroQol Group: Past, Present and Future.
Devlin NJ; Brooks R
Appl Health Econ Health Policy; 2017 Apr; 15(2):127-137. PubMed ID: 28194657
[TBL] [Abstract][Full Text] [Related]
12. The Limitations of EQ-5D as a Clinical Outcome Assessment Tool.
Gnanasakthy A; DeMuro CR
Patient; 2024 May; 17(3):215-217. PubMed ID: 38466537
[No Abstract] [Full Text] [Related]
13. A review of the psychometric performance of the EQ-5D in people with urinary incontinence.
Davis S; Wailoo A
Health Qual Life Outcomes; 2013 Feb; 11():20. PubMed ID: 23418844
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
